balovaptan

an orally administered selective vasopressin V1a receptor antagonist

Also Known As:

4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-5,6-dihydro-5-methyl-1-(trans-4-(2-pyridinyloxy)cyclohexyl)-; 8-Chloro-5-methyl-1-(trans-4-(2-pyridinyloxy)cyclohexyl)-5,6-dihydro-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine

Networked: 6 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - balovaptan: 6
  - Pyridines: 88
    - balovaptan: 6
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - Benzodiazepines: 8452
        balovaptan: 6

Experts

1.	Jacob, Suma: 3 articles (11/2022 - 01/2022)
2.	Sanders, Kevin: 3 articles (11/2022 - 01/2022)
3.	Smith, Janice: 3 articles (11/2022 - 01/2022)
4.	Veenstra-VanderWeele, Jeremy: 3 articles (11/2022 - 01/2022)
5.	Anagnostou, Evdokia: 2 articles (11/2022 - 01/2022)
6.	Ashford, Elizabeth: 2 articles (11/2022 - 01/2022)
7.	Hollander, Eric: 2 articles (11/2022 - 01/2022)
8.	Jou, Roger: 2 articles (11/2022 - 01/2022)
9.	McCracken, James: 2 articles (11/2022 - 01/2022)
10.	McNamara, Nora: 2 articles (11/2022 - 01/2022)

Related Diseases

1.	Autism Spectrum Disorder 01/01/2023 - "Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder." 01/01/2020 - "Ascertaining a V1a antagonist specific brain activity pattern by pharmacological magnetic resonance imaging in the rat played a seminal role in guiding optimization efforts, culminating in the discovery of balovaptan (RG7314, RO5285119) 1. In a 12-week clinical phase 2 study in adults with autism spectrum disorder balovaptan demonstrated improvements in Vineland-II Adaptive Behavior Scales, a secondary end point comprising communication, socialization, and daily living skills. " 01/01/2022 - "Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial." 01/01/2023 - "Publishing balovaptan as a possible treatment for autism spectrum disorder (ASD), greatly increased the interest in CNS-acting vasopressin antagonists. " 01/01/2020 - "Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder."
2.	Autistic Disorder (Autism) 11/01/2022 - "Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program."
3.	Panic Disorder (Panic Attack) 01/01/2022 - "Serious adverse events were reported for two (1%) participants in the balovaptan group (one each of suicidal ideation and schizoaffective disorder), and five (3%) participants in the placebo group (one each of suicidal ideation, panic disorder, limb abscess, urosepsis, colitis [in the same participant with urosepsis], and death by suicide). "
4.	Respiratory Tract Infections (Respiratory Tract Infection) 01/01/2022 - "The most common adverse events were nasopharyngitis (14 [9%] in the balovaptan group and 19 [12%] in the placebo group), diarrhoea (11 [7%] and 14 [9%]), upper respiratory tract infection (ten [6%] and nine [6%]), insomnia (five [3%] and eight [5%]), oropharyngeal pain (five [3%] and eight [5%]), and dizziness (two [1%] and ten [6%]). "
5.	Psychotic Disorders (Schizoaffective Disorder) 01/01/2022 - "Serious adverse events were reported for two (1%) participants in the balovaptan group (one each of suicidal ideation and schizoaffective disorder), and five (3%) participants in the placebo group (one each of suicidal ideation, panic disorder, limb abscess, urosepsis, colitis [in the same participant with urosepsis], and death by suicide). "

Related Drugs and Biologics

1.	Antidiuretic Hormone Receptor Antagonists
2.	Vasopressins (Vasopressin)